SLU-PP-332

SLU-PP-332 is a pan-agonist of estrogen-related receptors (ERRα/β/γ) that the community runs primarily as an exercise mimetic — people report using it to replicate endurance-training metabolic effects and support mitochondrial function, with positive sentiment running high across captured reports. Clinician sources split sharply on protocol: one recommends 1.5 mg subcutaneous twice daily for 6–8 weeks; another cites 100 mg orally daily — a wide divergence in both route and dose that has no consensus behind it. The honest caveat is that the evidence base is thin: no approved indications exist, and all human use is off-label with no completed trials to anchor the claims.

SLU-PP-332

Research Evidence

Evidence shape

No registered clinical trials exist for SLU-PP-332. The research sits entirely at the preclinical and mechanistic stage — no human studies have been initiated, let alone completed or posted results. Anyone pointing to human evidence for this compound is working from extrapolation, not data.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 thin / exploratory
Qualityhow rigorous
No completed trials
Breadth and depth2 rows captured
Human
direct clinical signal
0
Animal
translational support
0
In vitro
mechanistic support
2
HighMediumLow

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
Royal Peptides
USA/China
500 mg
$320.00
$0.64/mg
2
Peptira
US
60 mg
$99.00
$1.65/mg
3
EU Peptide Shop
Europe
50 mg
$113.00
$2.26/mg
4
High Purity Peptides
HK
50 mg
$120.00
$2.4/mg
5
Amc Essentials
US
30 mg
$99.99
$3.33/mg
6
Pro labs research
--
10 mg
$49.99
$5/mg

price offers can be sorted by column

1-6 of 35

Dosing & Protocol

How SLU-PP-332 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
1.5 mg
100 µg
250 µg
1 mg
5 mg
15 mg
Frequency
BID
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 1.5 mg BID subQ (1 source).

1 source
Anecdotal
Community-reported real-world use · n = 36
Typical dose
500 µg100 µg – 20 mg
typical
100 µg
250 µg
1 mg
5 mg
15 mg
distribution of 17 reported doses · darker = more reports
By reported cadence
Daily500 µg (100 µg–500 µg) · n=4
Schedule unstated400 µg (250 µg–20 mg) · n=13
Frequency
daily
Timing
unspecified
Route
oral / subQ
Cycle
unspecified

Reported doses span 100 µg–20 mg, most commonly 500 µg; most report daily dosing.

22 sources

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for SLU-PP-332, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.